Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-9 - PORT: Additive Chemotherapy vs Surveillance in mCRC
NCT05008809Phase 3Recruiting
- Start
- Dec 2021
- Primary completion
- Nov 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of fluorouracil, folinic acid, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, capecitabine in colorectal cancer (CRC). Started Dec 2021; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05008809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008809.